shape-zoom2 shape-zoom2 chevron-down edit share2 twitter youtube

Feature

The Shape of Drugs to Come

Protein engineers are using the building blocks nature provides to design an ever-expanding toolkit of new drug modalities to fight disease.

Explore the Feature

Feature

Probing Novel Biology

Amgen is using pioneering science to tackle drug targets where the genetic support is robust but the biology is mysterious.

Explore the Feature

Feature

The Passionate Pursuit of Nav 1.7

Recent research has shown that mutations in the gene for Nav 1.7, a sodium ion channel, can either ramp up pain or shut it down entirely. Amgen scientists are using creative approaches and unconventional tools to explore the potential of Nav 1.7 as a new drug target for pain.

Explore the Feature

Feature

Genetic Insights Fuel Alzheimer’s BACE Race

Amgen’s pursuit of Alzheimer’s treatments now includes a global collaboration with Novartis that focuses on the BACE gene, a target first cloned by Amgen and supported by genetic validation.

Explore the Feature

Feature

THE ULTIMATE PARASITE

Amgen’s head of Discovery Research, Alexander Kamb, discusses his view on why we get cancer, what makes it so difficult to treat, and why immunotherapeutic approaches look so promising.

Explore the Feature

About

About Amgen Science

Resource

PARTNERING WITH AMGEN

Resource

R&D STRATEGY

Feature

BETTER SCIENCE THROUGH BIOSIMILAR R&D

Amgen helped to develop the science used in making biologic medicines, and we remain a leader in designing and manufacturing new biologics. This expertise is now being applied to the challenge of making high-quality biosimilars.

Explore the Feature

News

Innovative AmBER Program Aims to Build New Bridges with Research Tools

News

Honoring the Scientist Who Pioneered the BiTE® Antibody Construct

Feature

THE NEW GENETICS